Growth-hormone and prolactin excess (Q48785419)

15 February 2018

review article

1 reference

title

Growth-hormone and prolactin excess (English)

1 reference

15 February 2018

1

A Colao

1 reference

15 February 2018

G Lombardi

2

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 October 1998

1 reference

15 February 2018

published in

The Lancet

1 reference

15 February 2018

volume

352

1 reference

15 February 2018

issue

9138

1 reference

15 February 2018

page(s)

1455-1461

1 reference

15 February 2018

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

1 reference

7 January 2021

Acromegaly, colonic polyps and carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

IGFBP‐3 is a poor parameter for assessment of clinical activity in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

A comparison of different methods for diagnosing acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Determinants of clinical outcome and survival in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Acromegaly--the place of the neurosurgeon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Effect of octreotide pretreatment on surgical outcome in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Radiation oncogenesis in relation to the treatment of pituitary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Acromegaly. Recognition and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Effect of different dopaminergic agents in the treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

1 reference

7 January 2021

Prostatic Hyperplasia: An Unknown Feature of Acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

The natural history of untreated hyperprolactinemia: a prospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Treatment of prolactinomas with megavoltage radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Management of prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Treatment of macroprolactinoma with cabergoline: a study of 85 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Decreased bone density in hyperprolactinemic women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Epidemiology of acromegaly in the Newcastle region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

1 reference

7 January 2021

Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Consensus statement: benefits versus risks of medical therapy for acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Growth hormone and the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Acromegaly: treatment after 100 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Prolactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Increase in bone mass after treatment of hyperprolactinemic amenorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Microprolactinomas: why requiem for surgery?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Hyperprolactinemia in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Progress in the management of hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

Pituitary imaging is essential for women with moderate hyperprolactinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903356-X

7 January 2021

10.1016/S0140-6736(98)03356-X

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018